THE REGULATION OF
rDNA TECHNOLOGY
DERIVED DRUGS:
BIOTECH SPECIFIC
ASPECTS

Conference Date: 11 Mar 2010
Conference Ref: B3-5510
Fee: £545 + VAT
Venue: The Rembrandt Hotel, London

WHY SHOULD YOU ATTEND?

• Gain a refresher/update on the technical aspects specific to the regulation of rDNA derived medicinal products
• Improve your knowledge of the differences between the regulation of rDNA products and conventional small molecule drugs
• Compare experiences with delegates from across Europe

* Please note – the seminar assumes a scientific background and a basic knowledge of drug regulatory affairs

WHO SHOULD ATTEND?

• Life scientists moving into biotech regulatory affairs
• Technical and scientific decision makers in biotech start up operations
• Those with a life science background in the financial sector involved in due diligence or regulatory portfolio
• Those from small molecule backgrounds transferring to biotech product regulatory affairs

CHAIRMAN

Dr Mark Richardson - Richardson Associates Regulatory Affairs Ltd

Click here to book your place.